---
title: "Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280656260.md"
description: "Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has published its audited annual results for the year ending December 31, 2025, reviewed by the board’s audit committee. The full annual report will be available by the end of April 2026. The announcement confirms the board's current composition, indicating governance stability. The latest analyst rating for the stock (HK:2315) is a Hold with a price target of HK$48.00. Biocytogen focuses on pharmaceutical R&D and is listed in Hong Kong under stock code 2315, with a market cap of HK$22.61B."
datetime: "2026-03-26T14:56:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280656260.md)
  - [en](https://longbridge.com/en/news/280656260.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280656260.md)
---

# Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an update.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has released its audited annual results for the year ended 31 December 2025, which have been reviewed by the board’s audit committee. The company stated that the annual results announcement includes the full text of its 2025 H-share annual report, prepared in line with Hong Kong listing rules on preliminary annual results disclosures.

The 2025 annual report is scheduled to be published on the Hong Kong Exchanges and Clearing website and the company’s own site by the end of April 2026. The announcement also confirms the current composition of the board, highlighting continuity in leadership under chairman and chief executive officer Shen Yuelei, which signals governance stability for investors and other stakeholders.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

**More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H**

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2315. The group focuses on pharmaceutical research and development and operates through multiple subsidiaries, targeting both domestic and international capital markets via its H-share listing.

**Average Trading Volume:** 1,913,740

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$22.61B

Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02315.HK](https://longbridge.com/en/quote/02315.HK.md)

## Related News & Research

- [Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees](https://longbridge.com/en/news/285576023.md)
- [Biocytogen Forecasts Profit Surge on Overseas Expansion and Industry Recovery in 2025](https://longbridge.com/en/news/274121607.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [When Can We Expect A Profit From Island Pharmaceuticals Limited (ASX:ILA)?](https://longbridge.com/en/news/286861950.md)
- [Biocytogen Sets Out Board Structure and Committee Roles](https://longbridge.com/en/news/275756980.md)